STOCK TITAN

Better Therapeutics to Participate in Three Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Better Therapeutics (NASDAQ: BTTX), a company focusing on prescription digital therapeutics, has announced its participation in three significant investor conferences in September 2022. These include the H.C. Wainwright 24th Annual Global Investment Conference on September 13, the Lake Street 6th Annual Best Ideas Growth Conference on September 14, and a virtual fireside chat at the LifeSci Partners HealthTech Symposium on September 20. The management team will also hold one-on-one meetings during these events and the fireside chat will be available for replay on their website.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO--(BUSINESS WIRE)-- Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe, Chief Executive Officer, along with other members of the company’s management team, will participate in three upcoming investor conferences in September 2022.

  • H.C. Wainwright 24th Annual Global Investment Conference being held in New York on September 13, 2022.
  • Lake Street 6th Annual Best Ideas Growth (BIG6) Conference being held in New York on September 14, 2022.
  • LifeSci Partners HealthTech Symposium being held virtually on September 20, 2022. Better Therapeutics will participate in a fireside chat at 2:45 p.m. ET / 11:45 a.m. PT.

Better Therapeutics management will be available for one-on-one meetings during the conferences. The webcast and replay of the LifeSci Partners HealthTech Symposium fireside chat will be available on the Presentations and Events page of the Better Therapeutics website at www.bettertx.com for approximately 30 days after the event.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications, if authorized for marketing, are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com

Investor Relations:

Mark Heinen

IR@bettertx.com

Media:

Ryan McKenna at Real Chemistry

rmckenna@realchemistry.com

Source: Better Therapeutics

FAQ

When is Better Therapeutics participating in investor conferences in September 2022?

Better Therapeutics will participate in investor conferences on September 13, 14, and 20, 2022.

What is the focus of Better Therapeutics' presentation at the conferences?

Better Therapeutics focuses on prescription digital therapeutics and nutritional cognitive behavioral therapy for cardiometabolic diseases.

Will Better Therapeutics hold one-on-one meetings during the conferences?

Yes, Better Therapeutics management will be available for one-on-one meetings during the conferences.

Where can I watch the LifeSci Partners HealthTech Symposium fireside chat?

The fireside chat will be available for replay on Better Therapeutics' website.

What is the significance of Better Therapeutics' participation in these conferences?

Participation in these conferences allows Better Therapeutics to engage with investors and showcase their innovative approaches to treating cardiometabolic diseases.

BETTER THERAPEUTICS INC

OTC:BTTX

BTTX Rankings

BTTX Latest News

BTTX Stock Data

5.45k
24.48M
48.23%
0.01%
3.9%
Biotechnology
Healthcare
Link
United States of America
San Francisco